Executive briefing: Piecing the puzzle together – reimbursement in the EU
This article was originally published in Clinica
Getting a medical device reimbursed is critical for its market adoption. In Europe, the complex and highly fragmented reimbursement landscape presents itself as a major challenge to medtech companies of all sizes. In this report, IBI analyst Phil Greenfield offers a guide to piecing together the reimbursement puzzle and an overview of reimbursement in the five major EU markets
You may also be interested in...
Artificial intelligence (AI) and machine learning took center stage at this year’s Radiological Society of North America meeting in Chicago, and the pervasiveness of AI tech in new product launches was further emphasized at the RSNA’s expanded AI Showcase exhibit.
The French start-up claims first-in-man success for heart valve “softening” treatment and plans further trials for an EU launch.
Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer
The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.